Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
188Re-SSS Lipiodol SIRT in Non-operable Hepatocellular Carcinoma
2023-503341-60-00Phase 2Completed
- Sponsor
- Centre Eugène Marquis
- Start
- Jul 2023
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rhenium-188-SSS lipiodol in hepatocellular carcinoma (HCC), sponsored by Centre Eugène Marquis. Primary endpoints: Objective response rate within 6 months by mRECIST, Best overall tumor response over 24 months and 4 more. Started Jul 2023; status: completed.
02
Drugs
rhenium-188-SSS lipiodol
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2023-503341-60-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503341-60-00.